iam_en_google_string,iam_en_improved_string \(make\)\( dangerous\)\(.*\)\(\.\),\1\3\2\4 and its discontinuation,and after its discontinuation after his arrest,after its discontinuation Adaptation,Adjustment adaptation,adjustment FITNESS dose,adjustment of the dose FITNESS,Adjust hyperkalimiants,hyperkalemiants hypokalimiants,hypokalemiants urinary excretion,urinary excretion hyperrflexivit,hyperreflexia v igil,alertness void making alcoholic beverages,void taking alcoholic beverages Surcharge alcohol,Alcohol may potential enzyme inducer,potential enzyme induction inductor,inducer downside risk efficiency.,risk of lowered efficacy. efficiency,efficacy Renal acute,Acute renal insufficiency the patient dehydrated,the dehydrated patient aggression on the gastroduodenal mucosa,infringement on the gastroduodenal mucosa aggression in the gastroduodenal mucosa,infringement of the gastroduodenal mucosa "Increase toxicity, especially hematologic, methotrexate","Increased toxicity, especially hematologic, from methotrexate" cyclins,cyclines cyclin ,cyclines iron salts of bisphosphonates distance,iron salts separately from the bisphosphonates by bisphosphonate),from the bisphosphonate) remote strontium salts of,strontium separately from salts of lincosanides remote,separately from the lincosanides of zinc distance,separately from the zinc fluorine distance,separately from the fluorine distance of,separately from the distance from,separately from the Distance,separately from the remote,separately from the when possible increase,at any increase cons-indicated or recommended,contra-indicated or inadvisable for the association,during concurrent use Association recommended,Concurrent use inadvisable Association not recommended,Concurrent use inadvisable association,concurrent use Association,Concurrent use Cons-pointer,Contra-indicated Cons-indications,Contra-indications Against-indication,Contra-indication Necessity of control,Necessity of establishing controls whatever the dose,irrespective of the dose clinical oversight and possibly biological,clinical and possibly biological oversight Precaution employment,Use with caution in case of alteration,in case of altered Precautions for use,Use with caution decreased renal clearance of methotrexate with anti-inflammatory,decreased renal clearance of methotrexate with anti-inflammatories decreased renal clearance by anti-inflammatory,decreased renal clearance by anti-inflammatories automatism,automaticity Decreased uricosuric effect of competition by the elimination of uric acid in renal tubules.,Decreased uricosuric effect via competition for elimination at the level of the renal tubules. "Potentiation of effects, both cytostatic and undesirable, the fluoro-uracil.","Potentiation of effects, both cytostatic and undesirable, by fluoro-uracil." to type of rhabdomyolysis,of a rhabdomyolytic type "Increase of nearly 5 times with ciclosporin, plasma concentrations of aliskiren increased risk of adverse effects.","Increase of nearly 5 times, with cyclosporin, in the plasma concentrations of aliskiren with increased risk of adverse effects." Bone marrow failure may be serious.,Potentially serious bone marrow failure. lorqui,when renal screening,advanced renal insufficiency Impaired contractility of automaticity and conduction,"Impaired contractility, automaticity and conduction" as in a regime dsod (uniraire decreased,as in a sodium-restricted regime (decreased urinary rythomycine,erythromycin clarithomycine,clarithomycin Increased adverse effects of colchicine with potentially fatal.,Increased adverse effects of colchicine with potentially fatal consequences. antihypertensive Central.,central antihypertensive. ulcerogenic.,ulcerogenic risk. used:, : without inconvenience,without adverse effect gel and by general oral haemorrhages unpredictable,generally and by buccal gel: unpredictable haemorrhages with immunosuppressive potential loss of power.,with potential loss of immunosuppressive power. its active metabolite fluoxetine.,its active metabolite by fluoxetine. and vasodilator antihypertensive central harmful heart failure treated with beta-blocker and vasodilator.,"and vasodilation by central antihypertensive, predisposed in heart failure treated with beta-blocker and vasodilator." by antisecretory.,by the antisecretory. (water retention steroids),(sodium and water retention by steroids) which represent one of the folate cofactors.,in which folate is a cofactor. reducing cardiovascular reactions by clearing beta-blockers.,reduced cardiovascular compensation by beta-blockers. reducing cardiovascular reactions compensation by beta-blockers.,reduced cardiovascular compensation by beta-blockers. with heart failure or uncontrolled latent,with latent or uncontrolled heart failure with latent heart failure or uncontrolled,with latent or uncontrolled heart failure excessive hemodynamic effect,excessive hemodynamic response excessive hemodynamic repercussion,excessive hemodynamic response "rational, useful for some patients, does not exclude the occurrence of hypokalemia, particularly in renal failure and diabetic hyperkalemia.","rational, useful for some patients, does not exclude the occurrence of hypokalemia nor, particularly in renal failure and diabetics, hyperkalemia." serotonin syndrome include diarrhea,serotonin syndrome : diarrhea in the non-cerebral,extra-cerebrally "Risk of elongation of the engine block, plus any deficit in part pseudocholinesterase.","Risk of prolongation of the motor block, particularly with partial pseudocholinesterase deficiency." (additive effects bradycardia),(additive bradycardic effects) Risk of decreased effectiveness of each antiviral competitive antagonist of the phosphorylation reaction at the origin of active metabolites.,"Risk of decreased effectiveness of each antiviral, by competitive antagonism of the phosphorylation reaction at the origin of active metabolites." acetylsalicylic acid-dose anti-inflammatory,acetylsalicylic acid at anti-inflammatory doses Risk of serious haematological effects increase.,Risk of increased serious haematological effects. including torsades de pointes type.,including torsades de pointes. Disease Risk widespread vaccination deadly.,Risk of fatal widespread vaccination illness. "Risk of vaccine, possibly fatal disease. This risk is increased in patients already immunosuppressed by the underlying disease.",Risk of possibly fatal vaccine illness. This risk is increased in patients already immunosuppressed by the underlying disease. inhibition of hepatic drug metabolism torsadogne,inhibition of hepatic drug metabolism by torsadogne torsades de pointes notammment.,notably torsades de pointes. f unction v entriculaire left,left ventricular function blood levels under control,guided by drug levels plasma levels under control,guided by drug levels acetylsalicylic acid doses used analgesics,acetylsalicylic acid in doses used for analgesics Whether to adjust,Possibly adjust "make any clinical monitoring, ECG and electrolyte.","establish clinical, ECG and electrolyte monitoring." "make a clinical, electrocardiographic and electrolytic.","establish clinical, ECG and electrolyte monitoring." another statin use is not concerned by this type of interaction.,use another statin not affected by this type of interaction. gastrointestinal and topical antacids,gastrointestinal topicals and antacids "Preventing ill and strengthen, especially early in treatment, self-monitoring blood.","Prevent illness and reinforce, especially early in treatment, blood self-monitoring." SMBG,glucose monitoring "Skip to insulin may, if necessary.","Switch to insulin, if necessary." Allow a two weeks,Allow a delay of two weeks Unless there hypokalemia.,Unless there exists hypokalemia. due diligence and monitoring of ECG QT monitored.,due diligence and monitoring of ECG QT. enhancing the clinical and ECG.,enhancing clinical and ECG monitoring. at doses recommended minimum.,at minimum recommended doses close clinical and ECG.,close clinical and ECG monitoring. with strict monitoring bacteriological indisputable justification.,"with strict, indisputable bacteriological monitoring." Clinical and ECG.,Clinical and ECG monitoring. especially in early,especially near initiating Clinical monitoring and possible digoxin during,Clinical monitoring and possible digoxin levels during "where applicable, the ECG and with digoxin dose adjustment of digoxin","where applicable, ECG and digoxin level measurement with dose adjustment of digoxin" A Case of rifampicin risk of significant rise in plasma concentrations of carvedilol,"At discontinuation of rifampicin, a risk of significant rise in plasma concentrations of carvedilol" ", ECG and digoxin,",", ECG and digoxin level measurement," "ECG and, possibly, digoxin.","ECG and, possibly, digoxin level measurement." "the digitoxinmie. If necessary, dose adjustment of digoxin","the digitoxinmie. If necessary, dose adjustment of digitoxin" the digitoxinmie,the measurement of digitoxin levels or prefer digoxin less metabolized by the liver.,or consider to instead use digoxin which is less metabolized by the liver. "digoxin, or prefer less metabolized by the liver.",or consider to instead use digoxin which is less metabolized by the liver. plasmatic,plasma monitoring Plasmatic,plasma monitoring ,Clinical monitoring dosages of posaconazole plasma,plasma-level based dosing of posaconazole monitoring of biological constants liver.,monitoring of liver parameters. adapted,adapting Use when there is an inactivated vaccine (polio).,Use an inactivated vaccine when it exists (polio). "Biomonitoring narrow potassium and creatinine (1 time per week during the first month, then once a month thereafter).","Close biomonitoring of potassium and creatinine (1 time per week during the first month, then once a month thereafter)."